RESEARCH DOSSIER
Life Insurance New Business Profitability and Value Metrics
Abstract. Life insurance new business profitability concerns the incremental economic contribution of contracts originated during a defined observation period, after the acquisition effort, expected contractual cash flows, expenses, insurance risks, financial guarantees, capital requirements, and relevant taxes have been recognized on a consistent basis. Its measurement is difficult because the same sale can generate a cash strain at inception, a positive projected long-run economic contribution, a contractual service margin released over future service, and a regulatory capital burden with an entirely different time profile. This monograph reconstructs the measurement chain connecting the new-business cohort, pricing assumptions, persistency, expense emergence, shareholder value, financial reporting, and prudential control. It critically compares actuarial profit-testing indicators, the CFO Forum's market-consistent embedded value approach, IFRS 17 accounting, United States life-insurance accounting and reserving, and European risk-capital concepts. An independently specified five-year hypothetical term-life cohort demonstrates how mortality, lapses, acquisition costs, maintenance expenses, and discounting change discounted contribution and its premium-normalized ratio. The central finding is that reliable profitability analysis requires an explicit unit of observation, consistent cash-flow and contract boundaries, a declared economic and accounting basis, and a bridge between the value assigned at issue and the profit subsequently emerging. Production, profitability, and policyholder outcomes must be examined together. The synthesis offers an auditable comparative interpretation of established practices and does not claim a new theory, model, or doctrine.
Keywords: Life insurance; new business profitability; value of new business; VNB; present value of new business premiums; PVNBP; market-consistent embedded value; MCEV; actuarial profit testing; insurance acquisition cash flows; contractual service margin; IFRS 17; persistency; lapse risk; expense emergence; risk capital; life-insurance pricing; cohort valuation.
Introduction
A life insurer writes a policy today whose commercial and economic effects can extend for decades. Sales reports commonly describe the contract at issue by an annualized premium, face amount, number of policies, or single-premium equivalent. These figures establish production volume, yet the financial consequence of originating a contract depends on mortality and survival, the duration of premium payments, the time pattern of commissions, underwriting expenditure, expense maintenance, the exercise of contract options, investment conditions, taxes, and the capital assigned to the undertaking. A policy can exhibit material first-year acquisition strain while producing positive discounted cash contribution; the opposite configuration can arise when strong early premium receipts conceal later guarantee or expense exposure.
The Actuarial Standards Board's life and annuity pricing standard (ASOP No. 54, revised 2018) expressly discusses several profitability metrics, including internal rate of return, return on equity, profit margin, value of new business, and break-even year. Their coexistence is scientifically consequential: each has a numerator, denominator, recognition horizon, and capital treatment, and therefore each addresses a distinct decision question. The CFO Forum's MCEV Principles (2016, Principle 10) prescribe a particular supplementary shareholder-value interpretation. The IFRS Foundation's IFRS 17 overview describes another objective: current measurement of insurance cash flows combined with recognition of profits as services are provided.
This study addresses three connected research questions. First, what is the economic object measured by new business profitability, and which contract and measurement boundaries determine that object? Second, how do pricing margins, acquisition costs, policyholder behavior, and the timing of maintenance expenses interact to determine expected contribution? Third, how should comparative valuation, accounting, capital, and stress indicators be interpreted without mistaking one measure for another?
The analysis uses original source-critical synthesis, normative comparison, an explicit deterministic numerical illustration, and sensitivity calculations. Regulatory requirements are identified with their jurisdiction and function. Published studies are reported within their observation populations. No proprietary insurer cash flows, policy-level longitudinal data, new empirical survey, or independently estimated behavioral model are represented as having been obtained. The numerical experiment is a transparent illustration rather than an actuarial rate recommendation. Scientific authorship consists of connecting sources across distinct reporting bases, deriving the conditional implications of their differences, and testing those implications against explicit cash-flow assumptions.
Foundations, Definitions, and Source-Critical Method
Defining the new-business unit
A new-business cohort is the population of contracts classified as newly originated within a defined reporting interval. At minimum, its identification requires a date of sale or initial recognition, product and underwriting characteristics, the contractual premium schedule, policy benefits, payment pattern, expected duration, currency, distribution channel, issue age, and the treatment of subsequent policy changes. The unit may be a policy, homogeneous modeling cell, contract group, insurance portfolio, reporting segment, or shareholder-owned covered-business population. A change in unit can change which cash flows and cross-subsidies are included.
The CFO Forum's definition of new business (2016, Principle 10 and Guidance G10.1-G10.4) includes new contracts and certain increases to existing contracts; expected renewal cash flows related to newly written business enter the new-business valuation, while ordinary experience deviations on existing renewals remain associated with in-force business. This distinction matters especially for flexible premiums and contract changes. Reclassifying renewal premiums as wholly new production can inflate sales-volume denominators while rearranging the attribution of future profit between new and old cohorts.
An economic increment must be defined relative to the resources required to originate and service the cohort. Let denote the number of policies issued at inception, the acquisition outlay, the premium received at time , claims and policy benefits, expenses, taxes, and capital-related cash costs or releases. For a consistently specified projection, an elementary shareholder-cash-flow representation is
where is the discount factor appropriate to the defined valuation basis. For actual product pricing, additional items may include assets and investment income, reserve contributions and releases, reinsurance, surrender values, investment guarantees, hedging, and the cost of options and nonhedgeable risks. The displayed expression is a bookkeeping abstraction, and an amount labeled becomes a standard-compliant value of new business only when all requirements of the selected standard are satisfied.
Four distinct financial questions
Economic value asks for the discounted shareholder contribution associated with origination. Accounting profit asks what recognized earnings should be reported in each financial period under the applicable accounting rules. Liquidity or new-business strain asks how much funding is needed as commissions and capital obligations arise before recurring margins. Capital efficiency asks what additional eligible capital is required, how long it is tied up, and how uncertain outcomes compare with available resources. A positive result in one dimension has no logical implication of a positive contemporaneous result in each other dimension.
A margin is always a ratio. Its interpretation requires a disclosed numerator, denominator, population, period, expense allocation, discount basis, and treatment of reinsurance. Percentage figures can be made larger by shortening or shrinking the premium denominator without increasing economic value. This is precisely why the CFO Forum's margin denominator guidance (G10.8) specifies value of new business divided by present value of new-business premiums (PVNBP), with other margins separately identified.
Evidentiary hierarchy and interpretation
This monograph uses original standards and regulator texts for formal definitions, directly issued professional studies for observed insurance experience, and academic literature for causal hypotheses, modeling choices, and empirical limitations. The hierarchy avoids treating a standard-setter's normative prescription as an empirical estimate or treating a single-country study as a universal behavior law.
The 2018 ASOP No. 54 establishes professional guidance for actuaries performing applicable life-insurance and annuity pricing work in its United States scope. The CFO Forum's 2016 MCEV materials provide supplementary reporting principles, not a mandatory global accounting standard. The accounting analysis draws on IFRS 17, effective for annual periods beginning on or after January 1, 2023, with details subject to the reporting entity's applicable version and jurisdictional endorsement. The US comparison draws on the FASB's long-duration accounting update (2018), without equating it with IFRS reporting.
One important limitation is temporal. The practices and studies referred to here are dated, and experience derived from policies issued years before observation may be affected by later rate environments and product redesign. The SOA/LIMRA 2015-2022 lapse study was published in December 2024 and uses specified US policy and contributor populations. A 2026 request for newer data is evidence of ongoing study collection, not completed results for 2023-2025.
New-Business Pricing Margins and Economic Value
From price to projected contribution
New-business pricing connects the insurer's promise to its planned financing. A level-premium life contract can generate an apparently stable premium stream while expected claims, maintenance effort, surrender incentives, and reserve needs vary sharply by duration. The premium is the contractual inflow. A pricing load for acquisition, ongoing expense, risk, capital, and profit is an allocation or planning construct rather than a separable asset. Determining economic profit requires the projected cash consequences of those allocations.
A useful decomposition distinguishes inception costs (underwriting, product issuance, distribution, initial commissions and onboarding), ongoing maintenance costs (billing, records, service, renewals, compliance and claims administration), claims and contractual payments, financing and reserve-related cash flows, and risk/capital costs. Fixed expenses allocated to a cohort should be distinguished from genuinely variable expenses: changing how shared overhead is allocated can alter a reported product margin without changing the insurer's total cash outlay.
This is a fundamental reason to value a cohort with full relevant expenses. The CFO Forum's Basis for Conclusions (2016, paragraphs 104-106) explains that new-business value is intended to represent value added from writing business, and it rejects substituting marginal expense treatment in a way that artificially inflates its contribution. Operational economies of scale may be real, but an analyst must establish whether the saving occurs in total enterprise expenditure or only in a product allocation.
Present value and profit-test indicators
For a defined cohort, discounted expected profit is obtained from cash flows after establishing when acquisition costs are paid and when claims and expenses emerge. In simple deterministic testing, is interpretable only after is stated precisely. Use of a single discount rate can serve a limited scenario exercise; it cannot substitute for a full market-consistent valuation of guarantees, asymmetric options, risk margins, and required-capital friction.
ASOP No. 54's profitability metric guidance explicitly invites more than one metric and appropriate sensitivity analysis. The internal rate of return (IRR) identifies a discount rate at which a specified cash-flow stream has zero present value, provided a suitable root exists. A present-value profit margin shows value relative to a stated premium base. The break-even year locates when cumulative profit first turns positive under a chosen convention. Return on equity conditions profits on capital allocation. These indicators can rank products differently even with identical premiums because the magnitude and timing of expenses and capital needs differ.
A simple comparison demonstrates the denominator effect. Suppose two homogeneous new-business cohorts each create $1 million of complete, comparably measured value. Cohort A has $20 million PVNBP and therefore a 5% VNB/PVNBP margin. Cohort B has $10 million PVNBP and therefore a 10% margin. Cohort B has the higher percentage, while both create the same absolute value. A sales target that maximizes the margin alone need not maximize total shareholder value. Equally, a larger total VNB may be obtained by multiplying a small margin by much greater volume, potentially requiring substantially more capital.
Market-consistent embedded value
The CFO Forum's MCEV valuation structure treats value of new business as additional shareholder value arising from newly written covered business, with relevant post-tax costs for financial options and guarantees, frictional costs of required capital, and residual nonhedgeable risks. Principle 10 explicitly addresses the distinction between new business and renewals; Guidance G10.7 establishes a post-tax value-of-new-business perspective; Guidance G10.8 defines its conventional margin.
A conceptual, non-reconciled decomposition is
where is the relevant present value of future shareholder profits, the time value of financial options and guarantees, frictional costs of required capital, and the cost of residual nonhedgeable risk, using the definitions of the selected MCEV implementation. The approximate notation warns against double deduction, because a particular presentation may incorporate some components upstream or apply its own tax conventions. A reproducible MCEV calculation needs the full documented measurement basis, not this schematic alone.
The accompanying MCEV conclusions justify PVNBP as conceptually aligned with VNB. An alternative based on annual premium equivalent or annualized new-business premium may be useful for sales interpretation but must not be silently presented as the same margin. Single-premium contracts are particularly sensitive to the denominator: the standard PVNBP captures the contractual premium horizon, whereas an annualized sales convention imposes a different transformation.
Boundary, valuation date, and management decisions
Assumption timing can change reported VNB even when actual contracts are identical. The CFO Forum's point-of-sale guidance (G10.6) regards point-of-sale assumptions as conceptually appropriate while recognizing practical difficulties, particularly when noneconomic assumptions are updated less frequently. An analyst comparing two annual periods must therefore distinguish genuine product profitability change from changes in economic conditions, model structure, assumptions, expense allocation, and business mix.
New-business value also depends on whether a sale consumes scarce capacity. A profitable policy written into a constrained capital position can displace a more valuable opportunity. Such opportunity cost is a management decision layer, not an automatic component of every published VNB. The relevant decision is whether incremental value remains attractive after all material constraints and foreseeable policyholder outcomes are assessed.
Persistency, Acquisition Strain, and Expense Emergence
Lapse as a state transition
A life policy can remain active, end through death or another insured event, expire by term, lapse without value, or terminate through surrender with a contractual payout. Persistency measures survival in the active contract state under a defined denominator and exposure convention. For a simplified annual projection, if is the conditional mortality rate and is the conditional lapse probability after the mortality transition, the probability of remaining premium-paying at the next duration is
The ordering of decrements is part of the model definition. In real portfolio studies, exposure calculations and competing-risk arrangements can differ; a lapse percentage without its exposure convention, duration, product classification, and termination treatment is incomplete. The SOA/LIMRA published term/whole-life study specifically explains its exposure methodology and includes both surrenders with value and forfeitures without value in its stated lapse measure.
The economic direction of a lapse depends on the contract. Early termination may remove future premium margins before acquisition cost is recovered. In another product, it can release guarantees or reduce adverse mortality liability. Universal life policies may involve premium nonpayment, depletion of account value, secondary guarantees, and distinct states. Consequently, a one-direction claim that higher lapse always harms profitability is unjustified. The cash-flow and option structure decides the sign and magnitude.
Evidence about policy behavior
The SOA Research Institute and LIMRA's 2024 experience summary reports 28 contributing companies, approximately 135.9 million policies exposed, and 5.4 million lapses or surrenders for its US individual term and whole-life observation design. These numbers measure a pooled exposure and termination record, not the lapse behavior of a hypothetical newly written cohort. The study describes restrictions to fully underwritten single-life policies and excludes certain workplace and simplified or guaranteed-issue products. Combining its counts into a single ratio would also conceal duration, product and exposure-weighting differences.
A separate SOA/LIMRA universal-life experience study reports approximately 11.9 million policy-count exposures for its premium-persistency component and about 33.5 million policy-years for its lapse/surrender component. Those populations, definitions, and measurement questions differ from whole-life and term contracts. Directly transferring a term-life lapse curve to a flexible-premium universal-life guarantee projection would therefore discard substantial contract structure.
Eling and Kiesenbauer's German policy-level analysis (2014) examines more than one million contracts and associates lapses with product and policyholder characteristics, including contract duration. Kiesenbauer's German insurer panel study (2012) finds that lapse relationships vary by product category, including a direction change for an aggregated unit-linked category. These are evidence for heterogeneity and potential interaction, not transferable causal parameters. The literature review by Eling and Kochanski (2013) identifies persistent modeling challenges and scarcity of accessible individual-level experience in its review of lapse research.
Expense strain and recoverability
At policy issue, distribution commissions and underwriting costs commonly arise before the business has generated sufficient cumulative renewal margins. Define cumulative discounted contribution after policy years by
The first break-even duration is the earliest for which is nonnegative, if such a duration exists. That date is sensitive to lapse rates because fewer surviving policies generate future premiums, whereas the original acquisition outlay was already incurred. The very same expense stream may also be sensitive to inflation: nominal maintenance expenses can rise by duration while premiums remain level.
Acquisition cost should not be evaluated solely by its ratio to first-year premiums. A high initial expense ratio can be justified economically by a sufficiently reliable lifetime margin, provided underwriting, guarantee, capital and customer outcomes are appropriate. Conversely, unusually low sales acquisition costs can coexist with future losses if the product contains expensive long-tail benefits. The required evidence is a complete, consistently timed projection.
For a multi-channel insurer, expense emergence must be distinguished between direct cost and allocation. Commissions genuinely payable on issue are a known contracted obligation. Administrative overhead is partly shared across products and generations. If a company assumes that an increasing sales volume will reduce unit maintenance costs, that assumption must be supported by operational capacity and cash spending. The CFO Forum's new-business expense rationale is directly relevant because cost-allocation changes otherwise create spurious value movements.
Behavior, selection, and customer outcomes
Mortality and lapse are often statistically dependent through policyholder health, income shocks, changing financial alternatives, and product design. A higher average lapse rate can change the mortality composition of remaining policies. Aggregate lapse and mortality stresses applied independently are helpful first diagnostics, but they do not capture selection effects unless a joint behavior and mortality structure is specified.
Distribution incentives affect both product mix and expense timing. If a seller is compensated mostly at issue, the institution bears the risk that a high-acquisition-cost contract terminates prematurely. Persistency-linked compensation or clawbacks can redistribute part of that risk but may influence advice and replacement incentives. New-business profitability is therefore linked to product suitability, clear surrender terms, and sustainable premiums. A financially attractive product remains subject to enforceable contract terms and applicable consumer-protection rules.
Profitability Risk Controls and Financial Reporting
IFRS 17: recognition is a different question
IFRS 17 combines current estimates of future insurance cash flows with a contractual service margin (CSM) that represents unearned profit for profitable groups of contracts. The IFRS Foundation's standard description identifies recognition of insurance-service performance over service periods as a central feature. The publicly accessible IFRS 17 consolidated text describes the treatment of insurance acquisition cash flows, profitable groups and onerous groups. Under the general measurement model, a positive expected future contribution ordinarily leads to a CSM rather than a day-one accounting gain, subject to the standard's detailed requirements.
When a group is onerous at initial recognition, the relevant net outflow produces an immediately recognized loss, with a zero CSM at initial recognition for that group. The onerous-group provisions in paragraph 47 make this asymmetry explicit. Therefore the accounting new-business CSM cannot be mechanically equated with a net aggregate shareholder VNB that contains positive and negative contract values. Aggregation and annual cohort requirements, contract boundaries, treatment of reinsurance held, discount rates, and risks differ.
Yousuf and coauthors' life-insurance CSM analysis (2021) explores the operational and commercial judgments involved in CSM measurement, including comparisons with new-business profitability measures. An insurer's management report can show VNB, new-business CSM and first-year earnings for the same sales period, but a coherent explanation must reconcile the populations, expense and risk treatment, discount basis, and the timing of subsequent service. There is no universal fixed conversion factor between these three indicators.
The IFRS Foundation's effects analysis of IFRS 17 explains that future service changes may adjust CSM, while experience relating to current or past service and onerous-group losses affect earnings differently. Profit emergence is therefore an accounting schedule subject to updated measurement, not simply a realization of an unchanged inception VNB.
US accounting and prudential reserves
United States GAAP follows its own long-duration accounting architecture. FASB's ASU 2018-12 communicates targeted amendments to Topic 944 involving liability assumptions and discounting, market-risk benefits, amortization of deferred acquisition costs, and disclosures. Its preface clarifies that the Accounting Standards Codification, rather than the Update itself, is the authoritative GAAP source. The financial statement treatment of acquisition costs should therefore be described with the relevant codified requirements and effective date applicable to a reporting entity; this is distinct from the cash outlay used in a pricing profit test.
The NAIC's principle-based reserving explanation describes the US transition toward reserve calculations responsive to product risk instead of relying solely on static prescribed formulas. The operative Valuation Manual began in 2017, while the framework's accreditation milestone followed in 2020. Principle-based reserves address policyholder protection and liability adequacy. Their magnitude does not serve as a direct measure of shareholder value, though changes in reserving and required assets can alter funding strain, available capital, and the profitability of writing additional business.
A concrete reconciliation therefore separates projected contractual cash flows, statutory or prudential reserves, GAAP or IFRS earnings, and discounted equity contributions. A reserve increase can reduce deployable resources immediately without representing a same-sized economic loss; equally, a release of reserves can improve near-term cash or statutory surplus without proving that the original pricing assumptions were sound.
European capital and governance
Solvency II identifies specific life-underwriting risk components. EIOPA's official Article 105 rulebook text lists mortality, longevity, disability-morbidity, expense, revision, lapse, and life-catastrophe risk components. This partition is useful for stress design because profitability assumptions can be wrong for different reasons. Mortality can raise claim costs, persistent maintenance inflation can erode margins, and mass lapse can change the availability of future premium inflows and the exercise of guarantees.
The Solvency II actuarial-function provision (Directive 2009/138/EC, Article 48) provides for coordination of technical provisions, examination of assumptions and data sufficiency, comparison with experience, views on underwriting and reinsurance, and contribution to risk management. This statutory governance responsibility supports independent review of the assumptions used to justify product profitability. It does not mean that a particular profit-test target is legally prescribed for all insurers or that one country's capital treatment transfers unchanged to another.
Institutional control design
Control of new-business profitability requires at least five linked activities: independent assumption setting; auditable model and product implementation; pricing and capital approval before launch; post-issue monitoring of actual lapses, claims, expenses, and product mix; and documented action when divergence becomes material. The role of governance is to preserve the meaning of the approved measurement basis as sales, rates, technologies and contract wording change.
The pricing standard's sensitivity analysis requirements support testing material uncertainty rather than reporting a single favorable point estimate. A reasonable stress suite varies mortality, early and late lapses, acquisition cost, maintenance cost, yield and reinvestment assumptions, guarantee exercise, reinsurance recoverability, taxes, and capital pressure. Joint scenarios are required where adverse outcomes are correlated, such as increasing lapse combined with weakened markets or elevated policyholder liquidity demand.
An accountability chain should identify who authored a model, sourced experience, approved a method, changed assumptions, authorized a product, and certified a reported KPI. Cross-functional review detects risk that disappears in a portfolio average or is transferred between accounting and management exhibits. Documentation makes the model reproducible when commercial conditions change.
Comparative Evidence, Worked Valuation, and Sensitivity Analysis
Research population and data limits
Comparative measurement cannot proceed by treating every publicly reported lapse statistic as directly comparable. The SOA/LIMRA term and whole-life study report covers participating US companies, defined policy types and historical anniversaries; its aggregate 135.9 million exposed policies and 5.4 million terminations combine multiple policy years and products. The later 2023-2025 study solicitation shows that a newer cohort-specific evidence update was being assembled. As of the research check, the solicitation is not equivalent to an issued final experience report.
The published German analysis of policyholder lapse determinants uses a single insurer's policy-level observations and historical market disruptions. Its regression associations help frame possible explanatory variables but cannot be applied quantitatively to all markets without external validation. Recession, inflation, changing interest rates, and consumer income volatility might affect cash-flow behavior differently by savings content and guarantee design. For this reason the following worked example adopts stated hypothetical assumptions instead of attaching the name of any external study to invented experience rates.
Transparent five-year cohort experiment
Consider 10,000 newly issued, identical five-year level-premium term policies. Each policy charges $500 at the start of a policy year, pays a hypothetical $100,000 on death during that year, and has an expected annual death rate of 0.15% while exposed. The simplified illustration deducts annual maintenance expense of $60 and premium-related charges of $15 per exposed policy, with an initial $350 acquisition outlay per original policy at time zero. Define the lapse rate as 7% at the end of the first year and 5% after each later policy year. Conditional annual mortality is 0.15% in every year. The discount rate for cash-flow illustration is 5% annually. All exposures and operating cash flows are assumed to occur at the beginning or end of a year only as specified below; for mathematical reproducibility, premiums, claims and expenses are netted into an illustrative year-end cash flow and discounted at the year end. This is not a representation of actual premium timing. Deaths and lapses occur before next year's exposure; end-of-year contract termination produces no additional surrender cash value.
Under these conventions, define and . The expected net contribution from a policy exposed at the start of a year is
For one original issued policy,
The projection is a deliberately stripped-down premium-minus-expected-claim-and-expense cash-flow contribution. It excludes reserve funding, investment assets and interest, taxes beyond the stated $15 charge, reinsurance, capital, cost of risk, financial options, benefit expenses not specified, catastrophe exposures, and stochastic experience. Accordingly, it must not be described as a standard-compliant MCEV VNB, statutory profitability, a GAAP profit, or an IFRS 17 CSM.
| Policy year | In-force proportion at start | Expected year-end net cash contribution per original policy | Cumulative discounted contribution, net of $350 acquisition cost |
|---|---|---|---|
| One | 1.000000 | $275.00 | -$88.10 |
| Two | 0.928605 | $255.37 | $143.53 |
| Three | 0.880852 | $242.23 | $352.78 |
| Four | 0.835554 | $229.78 | $541.82 |
| Five | 0.792585 | $217.96 | $712.60 |
The base-case discounted contribution equals $712.60 per originally issued policy, or approximately $7.126 million for the original 10,000-policy cohort. The discounted premium exposure is $1,931.99 per original policy. Their ratio is 36.88%. This is a premium-normalized simplified contribution ratio; calling it the MCEV-defined VNB/PVNBP would falsely imply that all mandated economic and capital adjustments had been performed. The cumulative present-value contribution first turns positive after the second projected policy year, reflecting the recovery of the inception acquisition expense.
Controlled one-at-a-time sensitivities
Recalculate the same formulas while varying just one specified input at a time. The high-lapse scenario uses 12% first-year lapse and 10% annual lapse in each later year. The mortality stress raises annual death probability from 0.15% to 0.20% and applies the new mortality rate consistently to deaths and surviving in-force contracts. The acquisition-cost stress raises inception outlay from $350 to $425. The expense stress raises annual maintenance cost from $60 to $80. The discount-rate stresses replace 5% with 3% and 7%. No optimization or refitting of assumptions is performed.
| Scenario | Discounted net contribution per original policy | Discounted premium exposure | Simplified contribution / premium |
|---|---|---|---|
| Base case | $712.60 | $1,931.99 | 36.88% |
| Higher lapses | $616.60 | $1,757.45 | 35.08% |
| Higher mortality | $518.62 | $1,930.27 | 26.87% |
| Higher acquisition expense | $637.60 | $1,931.99 | 33.00% |
| Higher maintenance expense | $635.32 | $1,931.99 | 32.88% |
| 3% discount rate | $771.55 | $2,039.17 | 37.84% |
| 7% discount rate | $658.49 | $1,833.62 | 35.91% |
All figures are rounded only for presentation; calculations use unrounded intermediate exposure proportions. The scenario isolates effects on this toy structure and makes no claim about actual product profitability. In the higher-lapse case, discounted net contribution decreases by $96.00 per issue. Its premium denominator also decreases, illustrating why interpretation should consider both absolute and normalized values. In the higher-mortality case, the expected death claim per exposed policy increases by $50 annually, which reduces the present value of net contribution by approximately $193.98. The survival effect marginally changes the denominator as well. Raising acquisition cost by $75 changes net present contribution by exactly $75 because the cost is paid at time zero in this design.
The discount-rate scenario is instructive. With exclusively positive projected year-end net operating cash flows after a fixed negative inception cost, a higher discount rate reduces the present value. A realistic life-insurance product with positive and negative future cash flows, reserves, interest-sensitive benefits, and asymmetric guarantees can have a more complicated response. The direction of the toy result therefore follows from the stipulated cash-flow sign pattern and is not a general empirical prediction.
Model reproducibility and mathematical scope
The example can be replicated using the following compact procedure. Set initial in-force proportion equal to one, acquisition cash flow to negative $350, and premium exposure to zero. For , add to the contribution value and to premium value, then update by multiplying by . Stress one input and repeat. This is sufficient to reproduce each table, including the break-even year, to the displayed rounding precision.
The sample design assumes an unobserved policyholder remains exposed throughout each policy year until a terminal decrement. It therefore makes no claim about exact actuarial exposure conventions, monthly premium timing, partial withdrawals, anti-selection, stochastic dependence, endogenous lapse behavior, model calibration, or observed mortality. Its scientific contribution is methodological transparency: the numerical results can be understood, challenged, and independently recalculated without proprietary spreadsheets.
Comparative interpretation
The case study supports four bounded inferences. First, greater policy persistence can improve recovery of initial expenses when each future policy year has positive expected incremental contribution. Second, higher mortality reduces cash contribution here because death benefits exceed collected risk premiums net of expenses. Third, accounting and capital results cannot be inferred from cash contribution alone. Fourth, any published percentage margin must name its denominator and the full set of costs it includes.
Actual comparability requires product cohorts aligned by issue date, underwriting quality and benefit type; payment and termination definitions; inflation and mortality assumptions; reporting currency; capital and tax conventions; treatment of contracts later modified; and observation or valuation horizon. Without this alignment, an apparent international profitability ranking may simply rank accounting conventions, product mix, or data completeness.
Integrated Scientific Findings and Measurement Governance
A coherent measurement bridge
A defensible management account begins with actual new-business production and its contract inventory; maps each contract to complete expected cash flows; establishes assumptions and capital; calculates a product-level economic contribution; produces reporting-basis measures such as VNB or CSM using their own standards; and then reconciles subsequent experience with the assumptions in force at the original valuation date.
This is an interpretation of existing insurance mathematics and reporting requirements. The bridge is analytically useful because it makes each transformation visible. It does not constitute a new valuation doctrine. Under IFRS 17, profitable insurance groups carry unearned CSM subject to release and remeasurement. Under MCEV, shareholder value reflects an explicitly defined market-consistent economic basis. Under a statutory solvency framework, prudential requirements constrain risk-taking and resources. Under internal pricing, management may apply a specific target return or capital budget. Each contributes information without collapsing into a single scalar truth.
The MCEV Principles require consistency of new and in-force valuation assumptions; the IFRS 17 reporting framework requires current estimates and a separately structured profit-recognition mechanism; the ASOP pricing guidance addresses the selection of more than one relevant profitability metric. Read together, they show why a technically credible profitability assessment contains a set of documented measures rather than a decontextualized number.
Reconciliation through time
At launch, valuation assumptions are prospective. Later reporting periods reveal actual mortality, lapse, expense, premium collection and capital usage. Variances can be assigned to experience, economic conditions, new assumptions, model updates, mix change, and management actions. A retrospective bridge should preserve the original valuation basis and identify subsequent changes rather than silently recalculating the historical result on today's assumptions and treating the difference as realized performance.
For example, when premiums lapse faster than anticipated, the insurer may collect less renewal income. A countervailing decline in expected benefit payments may occur, depending on product. In IFRS reporting, the effect on service-related margins depends on group-level rules and the distinction between future and current or past service. In embedded-value reporting, changes can be assigned to expected versus unexpected in-force movements. For capital, the impact will depend on the risk module and stress correlation. A multi-column reconciliation is therefore necessary for scientific interpretation.
Data provenance and validation
An auditable model requires source dates, valuation dates, product version, policy status, exposure method, mortality and lapse graduation basis, currency, discount curve or chosen rate, expense ledger, allocation rule, risk-capital method, reinsurance status and a list of deviations from the prior approved version. The SOA/LIMRA experience methodology illustrates why even an observed lapse ratio requires documented definitions and an identified contributing population.
The independent reviewer should test completeness of included cohorts, duplications, contracts outside policy boundaries, date mismatches, implausible negative or missing values, misclassified renewals, unexpected shifts in face amount and exposure, and unusual changes in expense allocation. Direct links from major assertions to original records and transparent calculation of illustrative figures strengthen reproducibility. A model cannot be validated by matching a favorable target margin alone; validation must investigate plausible adverse results.
Economic incentives and responsible decisions
Profitability governance has an institutional dimension. A product may look attractive when policyholders remain in force for many years but become unsustainable when its required premium rises sharply or its future service terms are difficult to understand. A distribution channel that maximizes issue counts may contribute less long-run value if acquisition cost and lapse are high. A guarantee with low near-term projected exercise may dominate tail outcomes when markets move sharply. These are reasons to integrate policyholder persistence, guarantee behavior, consumer outcomes, and capital capacity in the decision record.
EIOPA's life-underwriting risk classifications make the risk dimensions explicit, while the NAIC reserving account explains why valuation assumptions have prudential consequences beyond management profitability targets. A sustainable sales strategy is one in which projected value and the contractual commitments creating it remain feasible under reasonably severe adverse developments.
Original synthesis and scientific limits
The original synthesis of this monograph is the linked interpretation of six mechanisms: new policy identification; cash-flow and pricing contribution; persistence-dependent recovery of acquisition expenditure; complete expense emergence; reporting-basis transformation; and independent sensitivity and capital controls. Their interaction determines which statements about new-business profitability are warranted. This interpretation derives from the examined published standards, regulatory documents, and empirical literature. No newly invented general law or priority claim is made.
The principal limitations remain material. Country-specific insurance law, capital rules and accounting endorsements differ. Academic lapse evidence is partly observational, historical and jurisdiction-specific. Detailed SOA paid datasets were not analyzed; the public summaries were used within their reported scope. No original portfolio microdata or company-specific actuarial model was available. The five-year term-insurance experiment is hypothetical, deterministic, simplified and deliberately excludes many material components of real VNB. Full sensitivity to interest-rate guarantees and interacting policyholder actions requires a more complete model and additional evidence.
Conclusion
Life insurance new-business profitability is the expected incremental contribution associated with originating a defined cohort of policies, measured with a specified treatment of acquisition costs, future contract cash flows, risk, capital, tax and time. The measure acquires scientific meaning when its population, valuation date, cash-flow boundaries, assumptions, and denominator are stated. Value of new business, accounting contractual service margin, first-year earnings, premium volume and required capital answer related but distinct questions.
The analysis establishes that persistency and expense emergence are not auxiliary details: they determine whether initial acquisition spending is recovered through later premium and risk margins. Empirical evidence demonstrates substantial differences in lapse behavior by product and contract characteristics, which restricts the portability of aggregate lapse benchmarks. The transparent five-year calculation demonstrates how mortality, lapse, expense and discount-rate changes alter a clearly defined simplified contribution, while also showing why an incomplete cash-flow model cannot legitimately be described as a market-consistent value or IFRS accounting amount.
A reliable scientific and institutional assessment consequently combines complete profit testing, explicit metric reconciliation, observed experience with documented sampling limits, adverse-scenario sensitivity, independent assumption governance, and an account of consumer and capital consequences. That integrated practice supports rigorous comparison of newly originated life insurance business across products, periods and jurisdictions without claiming comparability that the underlying evidence cannot sustain.
References
Actuarial Standards Board. (2018). Actuarial Standard of Practice No. 54, Pricing of Life Insurance and Annuity Products. Adopted standard, last revised June 2018, effective December 1, 2018. Official standard.
Australian Accounting Standards Board. (2022, compiled version). AASB 17 Insurance Contracts. Public consolidated text with IFRS 17-equivalent provisions, including paragraph 47. Official text.
CFO Forum. (2016a). Market Consistent Embedded Value Principles. April 2016 edition. Principles and Guidance.
CFO Forum. (2016b). Market Consistent Embedded Value: Basis for Conclusions. April 2016 edition. Basis for Conclusions.
Eling, M., & Kiesenbauer, D. (2014). What policy features determine life insurance lapse? An analysis of the German market. Journal of Risk and Insurance, 81(2), 241-269. Publisher DOI.
Eling, M., & Kochanski, M. (2013). Research on lapse in life insurance: What has been done and what needs to be done? The Journal of Risk Finance, 14(4), 392-413. Publisher DOI.
European Insurance and Occupational Pensions Authority. (current rulebook presentation, accessed 2026). Calculation of the Basic Solvency Capital Requirement, Solvency II Directive Article 105. Official rulebook.
European Parliament and Council. (2009). Directive 2009/138/EC on the Taking-Up and Pursuit of the Business of Insurance and Reinsurance (Solvency II), Article 48. EUR-Lex directive. National implementing law and later amendments govern application.
Financial Accounting Standards Board. (2018). Accounting Standards Update No. 2018-12: Financial Services - Insurance (Topic 944), Targeted Improvements to the Accounting for Long-Duration Contracts. August 2018. Official accounting update.
IFRS Foundation. (2017). IFRS 17 Insurance Contracts: Effects Analysis. May 2017. Official effects analysis.
IFRS Foundation. (2026, accessed). IFRS 17 Insurance Contracts. Standard overview and issued-standard information. IFRS 17 overview.
Kiesenbauer, D. (2012). Main determinants of lapse in the German life insurance industry. North American Actuarial Journal, 16(1), 52-73. Publisher DOI.
National Association of Insurance Commissioners. (2025, last updated August 1). Principle-Based Reserving. Insurance Topics. NAIC guidance.
Society of Actuaries Research Institute & LIMRA. (2024a). 2015-2022 Term and Whole Life Insurance Policy Surrender/Lapse Experience Study Report. December 2024. Public PDF report.
Society of Actuaries Research Institute & LIMRA. (2024b). 2015-2022 Term/Whole Life Lapse/Surrender Experience Study. Study overview and contributor information. Study publication page.
Society of Actuaries Research Institute & LIMRA. (2024c). 2015-2021 Universal Life Premium Persistency and Lapse/Surrender Experience Study. Public summary. Experience study page.
Society of Actuaries Research Institute & LIMRA. (2026). 2023-2025 Term and Whole Life Lapse and Surrender Experience Study Data Request. Data solicitation, not a completed study. Research data request.
Yousuf, W., Stansfield, J., Malde, K., Mirin, N., Walton, R., Thorpe, B., Thorpe, J., Iftode, C., Tan, L., & Dyble, R. (2021). The IFRS 17 contractual service margin: A life insurance perspective. British Actuarial Journal, 26, e2. Cambridge DOI.